Download PDF
Thromb Haemost 2013; 109(01): 164-167
DOI: 10.1160/TH12-06-0389
Letters to the Editor
Schattauer GmbH

The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs

Hannah Lee
1   Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
,
Justin R. Hamilton
1   Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia
› Author Affiliations
Further Information

Publication History

Received: 12 June 2012

Accepted after major revision: 25 September 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264. DOI:10.1038/35025229.
    CrossrefPubMedGoogle Scholar
  • 2 Lee H, Hamilton JR. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Pharmacol Ther 2012; 134: 246-259. DOI:10.1016/j.pharmthera.2012.01.007.
    CrossrefPubMedGoogle Scholar
  • 3 Adams MN, Ramachandran R, Yau MK. et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 2011; 130: 248-282. DOI:10.1016/j.pharmthera.2011.01.003.
    CrossrefPubMedGoogle Scholar
  • 4 Goto S, Ogawa H, Takeuchi M. et al. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-2613. DOI:10.1093/eurheartj/ehq320.
    CrossrefPubMedGoogle Scholar
  • 5 Becker RC, Moliterno DJ, Jennings LK. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928. DOI:10.1016/S0140-6736(09)60230-0.
    CrossrefPubMedGoogle Scholar
  • 6 Ahn HS, Foster C, Boykow G. et al. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 2000; 60: 1425-1434. DOI:10.1016/S0006-2952(00)00460-3.
    CrossrefPubMedGoogle Scholar
  • 7 Mahajan SG, Fender AC, Meyer-Kirchrath J. et al. A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation. Thromb Haemost 2012; 108: 148-159. DOI:10.1160/TH11-11-0756.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Silini A, Ghilardi C, Ardinghi C. et al. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clin Exp Metastasis 2010; 27: 43-53. DOI:10.1007/s10585-009-9301-8.
    CrossrefPubMedGoogle Scholar
  • 9 Grisaru-Granovsky S, Maoz M, Barzilay O. et al. Protease activated receptor-1, PAR1, promotes placenta trophoblast invasion and beta-catenin stabilization. J Cell Physiol 2009; 218: 512-521. DOI:10.1002/jcp.21625.
    CrossrefPubMedGoogle Scholar
  • 10 Cheng Y, Kawamura K, Deguchi M. et al. Intraovarian thrombin and activated protein C signaling system regulates steroidogenesis during the periovulatory period. Mol Endocrinol 2012; 26: 331-340. DOI:10.1210/me.2011-1187.
    CrossrefPubMedGoogle Scholar
  • 11 Hocherl K, Gerl M, Schweda F. Proteinase-activated receptors 1 and 2 exert opposite effects on renal renin release. Hypertension 2011; 58: 611-618. DOI:10.1161/HYPERTENSIONAHA.111.173229.
    CrossrefPubMedGoogle Scholar
  • 12 El Eter EA, Aldrees A. Inhibition of Proinflammatory Cytokines by SCH79797, a Selective Protease-Activated Receptor 1 Antagonist, Protects Rat Kidney Against Ischemia-Reperfusion Injury. Shock 2012; 37: 639-644. DOI:10.1097/SHK.0b013e3182507774.
    CrossrefPubMedGoogle Scholar
  • 13 Yu CC, Hsu MJ, Kuo ML. et al. Thrombin-induced connective tissue growth factor expression in human lung fibroblasts requires the ASK1/JNK/AP-1 pathway. J Immunol 2009; 182: 7916-7927. DOI:10.4049/jimmunol.0801582.
    CrossrefPubMedGoogle Scholar
  • 14 Lee H, Sturgeon SA, Jackson SP. et al. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions. Thromb Haemost 2012; 107: 328-337. DOI:10.1160/TH11-06-0418.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Thevenet J, Angelillo-Scherrer A, Price M. et al. Coagulation factor Xa activates thrombin in ischemic neural tissue. J Neurochem 2009; 111: 828-836. DOI:10.1111/j.1471-4159.2009.06369.x.
    CrossrefPubMedGoogle Scholar
  • 16 Gluck N, Schwob O, Krimsky M. et al. Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. Am J Physiol Cell Physiol 2008; 294: C1597-1603. DOI:10.1152/ajpcell.00206.2007.
    CrossrefPubMedGoogle Scholar
  • 17 Meoli DF, White RJ. Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. Am J Physiol Lung Cell Mol Physiol 2009; 297: L706-714. DOI:10.1152/ajplung.90598.2008.
    CrossrefPubMedGoogle Scholar
  • 18 Ohuchi N, Hayashi K, Iwamoto K. et al. Thrombin-stimulated proliferation is mediated by endothelin-1 in cultured rat gingival fibroblasts. Fundam Clin Pharmacol 2010; 24: 501-508. DOI:10.1111/j.1472-8206.2009.00786.x.
    PubMedGoogle Scholar
  • 19 Lo HM, Chen CL, Tsai YJ. et al. Thrombin induces cyclooxygenase-2 expression and prostaglandin E2 release via PAR1 activation and ERK1/2- and p38 MAPK-dependent pathway in murine macrophages. J Cell Biochem 2009; 108: 1143-1152. DOI:10.1002/jcb.22341.
    CrossrefPubMedGoogle Scholar
  • 20 Chang LH, Chen CH, Huang DY. et al. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1alpha translational pathway in colorectal cancer cells. J Cell Physiol 2011; 226: 1060-1068. DOI:10.1002/jcp.22428.
    CrossrefPubMedGoogle Scholar
  • 21 Nadal-Wollbold F, Bocquet A, Bourbon T. et al. Protease-activated receptor 1 antagonists prevent platelet aggregation and adhesion without affecting thrombin time. Eur J Pharmacol 2010; 644: 188-194. DOI:10.1016/j.ejphar.2010.07.013.
    CrossrefPubMedGoogle Scholar
  • 22 Heemskerk JW, Willems GM, Rook MB. et al. Ragged spiking of free calcium in ADP-stimulated human platelets: regulation of puff-like calcium signals in vitro and ex vivo. J Physiol 2001; 535: 625-635. DOI:10.1111/j.1469-7793.2001.00625.x.
    CrossrefPubMedGoogle Scholar
  • 23 Offermanns S, Toombs CF, Hu YH. et al. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 183-186. DOI:10.1038/38284.
    CrossrefPubMedGoogle Scholar
  • 24 Schoenwaelder SM, Jarman KE, Gardiner EE. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674. DOI:10.1182/blood-2011-04-347849.
    CrossrefPubMedGoogle Scholar
  • 25 Di Serio C, Pellerito S, Duarte M. et al. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol 2007; 101: 63-69. DOI:10.1111/j.1742-7843.2007.00078.x.
    CrossrefPubMedGoogle Scholar